Cargando…

Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area

Aflatoxin B1 (AFB1) is a class 1 carcinogen with an ascertained role in the development of hepatocellular carcinoma (HCC) in high exposure areas. Instead, this study aimed to assay whether chronic/intermittent, low-dose AFB1 consumption might occur in low-exposure geographical areas, ultimately accu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gramantieri, Laura, Gnudi, Federica, Vasuri, Francesco, Mandrioli, Daniele, Fornari, Francesca, Tovoli, Francesco, Suzzi, Fabrizia, Vornoli, Andrea, D’Errico, Antonia, Piscaglia, Fabio, Giovannini, Catia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024438/ https://www.ncbi.nlm.nih.gov/pubmed/35458213 http://dx.doi.org/10.3390/nu14081652

Ejemplares similares

Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma
por: Giovannini, Catia, et al.
Publicado: (2023)

Evaluation of Toxicant-Associated Fatty Liver Disease and Liver Neoplastic Progress in Sprague-Dawley Rats Treated with Low Doses of Aflatoxin B1 Alone or in Combination with Extremely Low Frequency Electromagnetic Fields
por: Vornoli, Andrea, et al.
Publicado: (2022)

Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research
por: Fornari, Francesca, et al.
Publicado: (2022)

MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma
por: Gramantieri, Laura, et al.
Publicado: (2021)

Hepatic Cancer Stem Cells: Molecular Mechanisms, Therapeutic Implications, and Circulating Biomarkers
por: Gramantieri, Laura, et al.
Publicado: (2021)

Direct Antiviral Treatments for Hepatitis C Virus Have Off-Target Effects of Oncologic Relevance in Hepatocellular Carcinoma
por: Giovannini, Catia, et al.
Publicado: (2020)

Notch Signaling Regulation in HCC: From Hepatitis Virus to Non-Coding RNAs
por: Giovannini, Catia, et al.
Publicado: (2021)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma
por: Gramantieri, Laura, et al.
Publicado: (2022)

MicroRNAs in Animal Models of HCC
por: Fornari, Francesca, et al.
Publicado: (2019)

Brivanib in combination with Notch3 silencing shows potent activity in tumour models
por: Giovannini, Catia, et al.
Publicado: (2019)

MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma
por: Bergamini, Christian, et al.
Publicado: (2023)

Tissue miRNA 483-3p expression predicts tumor recurrence after surgical resection in histologically advanced hepatocellular carcinomas
por: Vasuri, Francesco, et al.
Publicado: (2018)

Treatment of Combined Hepatocellular and Cholangiocarcinoma
por: Leoni, Simona, et al.
Publicado: (2020)

Targeting Notch3 in Hepatocellular Carcinoma: Molecular Mechanisms and Therapeutic Perspectives
por: Giovannini, Catia, et al.
Publicado: (2016)

Role of microRNAs in the main molecular pathways of hepatocellular carcinoma
por: Vasuri, Francesco, et al.
Publicado: (2018)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Liver collision lesion: inflammatory hepatocellular adenoma within focal nodular hyperplasia
por: Renzulli, Matteo, et al.
Publicado: (2020)

Pathobiological and Radiological Approach For Hepatocellular Carcinoma Subclassification
por: Vasuri, Francesco, et al.
Publicado: (2019)

Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma
por: Giovannini, Catia, et al.
Publicado: (2014)

Challenging liver lesions in noncirrhotic patients: Report of three cases
por: Franceschini, Tania, et al.
Publicado: (2019)

A practical histological approach to the diagnosis of autoimmune hepatitis: experience of an Italian tertiary referral center
por: Franceschini, Tania, et al.
Publicado: (2021)

COVID-19: Has the Liver Been Spared?
por: Brandi, Nicolò, et al.
Publicado: (2023)

MicroRNAs as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing?
por: Gramantieri, Laura, et al.
Publicado: (2022)

Correlation of molecular alterations with pathological features in hepatocellular carcinoma: Literature review and experience of an Italian center
por: Maloberti, Thais, et al.
Publicado: (2022)

Lung Ultrasound Is Often, but Not Always, Normal in Healthy Subjects: Considerations for COVID-19 Pandemic
por: Raiteri, Alberto, et al.
Publicado: (2021)

TP53/MicroRNA Interplay in Hepatocellular Carcinoma
por: Pollutri, Daniela, et al.
Publicado: (2016)

Corrigendum: Vidatox 30 CH has tumor activating effect in hepatocellular carcinoma
por: Giovannini, Catia, et al.
Publicado: (2017)

Venom from Cuban Blue Scorpion has tumor activating effect in hepatocellular carcinoma
por: Giovannini, Catia, et al.
Publicado: (2017)

Prognosis of Single Early-Stage Hepatocellular Carcinoma (HCC) with CEUS Inconclusive Imaging (LI-RADS LR-3 and LR-4) Is No Better than Typical HCC (LR-5)
por: Terzi, Eleonora, et al.
Publicado: (2022)

Very Low Alcohol Consumption Is Associated with Lower Prevalence of Cirrhosis and Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease
por: Ferri, Silvia, et al.
Publicado: (2022)

Aflatoxin exposure assessed by aflatoxin albumin adduct biomarker in populations from six African countries: REVIEW ARTICLE
por: Xu, Y., et al.
Publicado: (2018)

LncRNAs as novel players in hepatocellular carcinoma recurrence
por: Gramantieri, Laura, et al.
Publicado: (2018)

Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC
por: Granito, Alessandro, et al.
Publicado: (2021)

Beneficial Prognostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders
por: Ielasi, Luca, et al.
Publicado: (2021)

Prognostic Impact of Metastatic Site in Patients Receiving First-Line Sorafenib Therapy for Advanced Hepatocellular Carcinoma
por: Ielasi, Luca, et al.
Publicado: (2023)

Diffuse Calcifications Protect Carotid Plaques regardless of the Amount of Neoangiogenesis and Related Histological Complications
por: Vasuri, Francesco, et al.
Publicado: (2015)

Pathological features and outcomes of incidental renal cell carcinoma in candidate solid organ donors
por: Ambrosi, Francesca, et al.
Publicado: (2020)

Case report: Histological findings of peri-appendicitis in three children with SARS-CoV-2 – related multisystem inflammatory syndrome: A mark for systemic inflammation?
por: Fabi, Marianna, et al.
Publicado: (2022)

TRANS-TACE: Prognostic Role of the Transient Hypertransaminasemia after Conventional Chemoembolization for Hepatocellular Carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dqfg4b0ecdunvm7bgd5ngt8g7r